# Transcriptional profiles predict treatment outcome in 1 patients with tuberculosis and diabetes at diagnosis and at 2 two weeks after initiation of anti-tuberculosis treatment 3 Authors 4 Cassandra L.R. van Doorn<sup>1,#</sup>, Clare Eckold<sup>2,#</sup>, Katharina Ronacher<sup>3,4</sup>, Rovina Ruslami<sup>5,6</sup>, 5 Suzanne van Veen<sup>1</sup>, Ji-Sook Lee<sup>2</sup>, Vinod Kumar<sup>7,8</sup>, Sarah Kerry-Barnard<sup>9</sup>, Stephanus T. 6 Malherbe<sup>3</sup>, Léanie Kleynhans<sup>3</sup>, Kim Stanley<sup>3</sup>, Philip C. Hill<sup>10</sup>, Simone A. Joosten<sup>1</sup>, Reinout 7 van Crevel<sup>8,11</sup>, Cisca Wijmenga<sup>7</sup>, Julia A. Critchley<sup>9</sup>, Gerhard Walzl<sup>3</sup>, Bachti Alisjahbana<sup>5,6</sup>, 8 Mariëlle C. Haks<sup>1</sup>, Hazel M. Dockrell<sup>2</sup>, Tom H. M. Ottenhoff<sup>1</sup>, Eleonora Vianello<sup>1\*</sup> and 9 Jacqueline M. Cliff<sup>2\*</sup>, on behalf of the TANDEM Consortium<sup>\$</sup> 10 <sup>#</sup>These authors contributed equally to this work 11 <sup>\*</sup>These authors contributed equally to this work 12 13 **Correspondence:** 14 Dr. Eleonora Vianello 15 Email: e.vianello@lumc.nl 16 Telephone: +31 71 52 63844 17 ORCID: 0000-0003-0342-4055 18 19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 20 <sup>1</sup>Department of Infectious Diseases, Leiden University Medical Center, Leiden, The
- 21 Netherlands
- <sup>2</sup>Dept of Infection Biology and TB Centre, London School of Hygiene & Tropical Medicine,
- 23 London, WC1E 7HT, United Kingdom
- <sup>3</sup>SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical
- 25 Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of
- 26 Medicine and Health Sciences, Department of Biomedical Sciences, Stellenbosch University,
- 27 Cape Town, South Africa
- <sup>4</sup>Mater Research Institute The University of Queensland, Translational Research Institute,
- 29 Brisbane, QLD, Australia
- <sup>5</sup>TB-HIV Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
- <sup>6</sup>Hasan Sadikin General Hospital, Bandung, Indonesia
- <sup>32</sup> <sup>7</sup>University of Groningen, University Medical Center Groningen, Department of Genetics,
- 33 Groningen, the Netherlands
- <sup>8</sup>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud
- 35 University Medical Center, Nijmegen, the Netherlands
- <sup>9</sup>Population Health Research Institute, St George's Hospital Medical School, University of
- 37 London.
- <sup>10</sup>Centre for International Health, Division of Health Sciences, University of Otago, Dunedin,
- 39 New Zealand
- 40 <sup>11</sup>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 41 University of Oxford, Oxford, UK
- 42

#### 43 Abstract

#### 44 Background

Globally, the anti-tuberculosis (TB) treatment success rate is approximately 85%, with treatment failure, relapse and death occurring in a significant proportion of pulmonary TB patients. Treatment success is lower among people with diabetes mellitus (DM). Predicting treatment failure early after diagnosis would allow early treatment adaptation and may improve global TB control.

#### 50 Methods

51 Samples were collected in a longitudinal cohort study of adult TB patients with or without 52 concomitant DM from South Africa and Indonesia to characterize whole blood transcriptional 53 profiles before and during anti-TB treatment, using unbiased RNA-Seq and targeted gene 54 dcRT-MLPA.

#### 55 Findings

We report differences in whole blood transcriptome profiles, which were observed before initiation of treatment and throughout treatment, between patients with a good versus poor anti-TB treatment outcome. An eight-gene and a 22-gene blood transcriptional signature distinguished patients with a good treatment outcome from patients with a poor treatment outcome at diagnosis (AUC=0.815) or two weeks (AUC=0.834) after initiation of anti-TB treatment, respectively. High accuracy was obtained by cross-validating this signature in an external cohort (AUC=0.749).

#### 63 Interpretation

64 These findings suggest that transcriptional profiles can be used as a prognostic biomarker for65 treatment failure and success, even in patients with concomitant DM.

#### 66 Funding

- 67 The research leading to these results, as part of the TANDEM Consortium, received funding
- 68 from the European Community's Seventh Framework Programme (FP7/2007-2013 Grant
- 69 Agreement No. 305279) and the Netherlands Organization for Scientific Research (NWO-TOP
- 70 Grant Agreement No. 91214038).

71

### 72 **Keywords (4-6)**

73 Biomarkers, tuberculosis, treatment outcome, diabetes mellitus

74

### 75 Introduction

With more than 10 million new cases and approximately 1.5 million deaths annually, tuberculosis (TB), which is caused by *Mycobacterium tuberculosis* (*Mtb*), continues to be a major global health threat.<sup>1</sup> Upon infection with *Mtb*, 5-10% of adults develop active disease during their lifetime and one quarter of the world's population is estimated to be latently infected with *Mtb* (LTBI). The global anti-TB treatment success rate is only about 85% and even lower in patients with multi-drug resistant TB or with comorbidities like HIV or diabetes mellitus (DM)<sup>1-3</sup>, resulting in a significant number of patients with poor clinical outcomes.

B3 DM triples the risk of developing active TB<sup>4</sup> and increases the risk of poor clearance of B4 the infection following anti-TB treatment.<sup>5-7</sup> In 2020, 0·37 million TB cases were estimated to B5 suffer from DM comorbidity.<sup>1</sup> 85-95% of all DM cases is attributed to type-2 diabetes mellitus B6 (T2DM).<sup>8</sup> Since global DM prevalence is estimated to rise from 463 million people in 2019 to B7 700 million in 2045<sup>9</sup>, in particular in areas where TB is endemic, there is increasing concern B8 about the consequences of the rising DM prevalence for global TB control.<sup>1</sup> The mechanisms B9 underlying DM-induced treatment failure remain, however, poorly understood.

90 Prediction of treatment failure based on sputum-smear microscopy and mycobacterial culture lacks sensitivity<sup>10</sup> and depends on the quality of sputum samples, which are difficult to 91 collect and are frequently inconsistent in quality.<sup>11-13</sup> In addition to more advanced sputum-92 based diagnostics, monitoring of whole blood transcriptomics may be an additional, 93 complementary but independent method to monitor treatment responses, possibly with 94 increased sensitivity.<sup>14</sup> Numerous studies have reported transcriptional biomarker profiles for 95 active TB and response to anti-TB treatment using whole-blood or PBMCs in settings with 96 varying TB incidence.<sup>15-20</sup> In addition, multiple studies have demonstrated the predictive 97 potential of host gene biomarkers in identifying patients at risk of developing active TB, relapse 98 and treatment failure.<sup>21-28</sup> Together, these studies showed that gene signatures may have utility 99

at predicting anti-TB treatment success versus failure already early after TB diagnosis,
 providing a significant improvement over the currently used low sensitivity conversion to
 negative sputum-based culture testing.<sup>10</sup> Despite the high incidence of DM and pre-DM among
 TB patients in TB-endemic settings<sup>7,29-31</sup>, only a few studies have identified or validated such
 signatures in TB patients with DM or hyperglycemia.<sup>32,33</sup>

Characterizing transcriptomic profiles may improve our understanding towards the 105 immunological pathways that are involved in DM-associated TB pathology and monitoring 106 treatment success and failure in TB patients with concomitant DM is key to combat the 107 108 tuberculosis-diabetes (TB-DM) co-epidemic. Although the blood transcriptome profile of TB-DM patients is more similar to TB patients than to DM patients, suggesting a dominant 109 influence of active TB infection, we and others recently demonstrated significant differences 110 in the blood transcriptome of TB-DM patients compared to TB patients.<sup>32,33</sup> Additionally, the 111 transcriptomic profiles of patients with TB-related intermediate hyperglycemia (TBrel-IH) 112 were similar to the profiles of TB-DM patients.<sup>32</sup> Importantly, we also showed that DM 113 comorbidity lowered the performance of published diagnostic biomarker signatures.<sup>32</sup> 114 Therefore, there is a need for biomarkers that predict treatment success and failure in TB 115 patients independently of their glycemia or DM status. 116

The aim of the current study was to identify blood transcriptional gene signature for predicting the anti-TB treatment outcome at an early stage after initiation of anti-TB treatment, irrespective of concomitant DM. We combined an unbiased RNA-Seq approach and a selective dcRT-MLPA approach (a multiplex RT-PCR platform) as two independent strategies to identify gene signatures with high discriminatory power to distinguish patients with a good treatment outcome from patients with a poor treatment outcome. Host gene biomarker profiles to identify anti-TB treatment success or failure could facilitate the evaluation of new anti-TB

drugs and improve clinical surveillance of TB patients, even in settings with high DMincidence.

126

148

#### 127 Methods

#### 128 <u>Study participant recruitment, classification and treatment</u>

Adult pulmonary TB patients were recruited as part of the TANDEM project<sup>29</sup> in two locations: 129 Bandung in Indonesia (UNPAD) and Cape Town in South Africa (SUN). All TB patients were 130 newly diagnosed and microbiologically confirmed, and included people with TB-DM. The TB-131 DM group included participants with both pre-diagnosed DM and newly identified DM, with 132 new diagnosis based on a laboratory HbA1c test  $\geq 6.5\%$  with a confirmatory HbA1c test  $\geq 6.5\%$ 133 or fasting blood glucose  $\geq$ 7 mmol/L at TB diagnosis<sup>29</sup>, followed by a further HbA1c test  $\geq$ 6.5% 134 135 after 6 months of TB treatment. The TB patients without DM included people with a normal glycaemic index (laboratory HbA1c <5.7%) at TB diagnosis ("TB-only"). Patients whose 136 137 HbA1c test results were  $\geq$  5.7% and < 6.5% at both TB diagnosis and at 6 months were deemed to have pre-diabetes ("TB-preDM") and patients with raised glycaemia at TB diagnosis but 138 below the cut-off for DM diagnosis (5.7% laboratory HbA1c <6.5%) were deemed to have 139 TB-related intermediate hyperglycaemia ("TBrel-IH"). In South Africa, healthy controls 140 without TB or DM were also recruited for baseline sample analysis. Multi-drug-resistant TB, 141 HIV positivity, pregnancy, serious co-morbidity and corticosteroid use were exclusion criteria. 142 TB patients received standard first line TB treatment according to WHO Guidelines. 143 Microbiological measures recorded at baseline and throughout treatment included sputum 144 smear and culture, with time to positivity (TTP) in mycobacteria growth indicator tubes 145 (MGIT) also assayed in South Africa. TB patients were classified based on their treatment 146 outcome: "poor treatment outcome" included those patients who died, failed initial treatment 147

(remained sputum positive at five months) or experienced TB-recurrence in the 12 month

follow-up period post treatment, whilst those with "good treatment outcome" had successful
TB treatment without subsequent recurrence. Patients for whom the outcome data were missing
were not included in downstream analyses. Most TB-DM patients received local standard of
care DM treatment, whilst a subgroup in Indonesia received more intensive HbA1c monitoring
and treatment adjustment through TB treatment as part of a pragmatic randomised control
trial.<sup>34</sup>

#### 155 <u>Ethics Statement</u>

The study was approved by the London School of Hygiene & Tropical Medicine Observational
Research Ethics Committee (6449), the SUN Health Research Ethics Committee (N13/05/064)
and the UNPAD Health Research Ethics Committee, Faculty of Medicine, Universitas
Padjadjaran (number 377/UN6.C2.1.2/ KEPK/ PN), and participants gave written informed
consent.

#### 161 <u>RNA sample collection and extraction</u>

Patient samples were collected prior to initiation of treatment (diagnosis), at weeks 2, 4, 8, 16
and 26 through treatment, and at 12 months after TB diagnosis, and from HC at baseline only.
Venous blood (2.5ml) was collected into PAXgene Blood RNA Tubes (PreAnalytiX). Total
RNA was extracted using RNeasy spin columns (Qiagen) and quantified by Nanodrop
(Agilent). The LabChip GX HiSens RNA system (PerkinElmer) was used for quality
assessment of samples processed by RNA-Seq.

#### 168 <u>Unbiased RNA-Seq of global gene expression</u>

Samples collected at TB diagnosis and weeks 2, months 2, and months 6 from the first 63 participants recruited were analysed by RNA-Seq (Table 1). Libraries were generated using the poly-A tail Bioscientific NEXTflex-Rapid-Directional mRNA-Seq method with the Caliper SciClone. Single-end sequencing was performed using the NextSeq500 High Output kit V2

(Illumina) for 75 cycles. Sequence data from FASTQ files were aligned to the Human g1kv37
reference genome, using STAR (v2.5.1b).<sup>35</sup> Quality control was performed with FastQC<sup>36</sup>,
while transcript quantification was performed using HT-seq count (v0.61)<sup>37</sup>: lowly expressed
transcripts (<50 counts across all samples), were removed from the downstream analysis.</li>
RNA-Seq data were normalised using DESeq2 (v1.30.0).<sup>38</sup>

# 178 <u>Dual-color Reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-</u> 179 <u>MLPA</u>)

Dual-color reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-180 MLPA) was performed on all samples to identify blood transcriptional profiles as described 181 previously.<sup>39</sup> Brief descriptions are provided in the Supplementary Information. RT primers 182 and half-probes were designed by Leiden University Medical Centre (LUMC, Leiden, The 183 Netherlands) and encompassed sequences for 144 selected key immune-related genes to profile 184 the innate, adaptive and inflammatory immune responses (Supplementary Table S1), and four 185 186 housekeeping genes (GAPDH, ABR, GUSB, B2M). Genes with an adjusted p-value <0.05 (Benjamini-Hochberg<sup>40</sup>) and a log2-fold change (FC) <-0.6 and >0.6 were considered 187 differentially expressed genes (DEGs). Genes that were below the detection limit in >90% of 188 189 the samples per cohort were excluded from analysis.

#### 190 *Data analysis and Statistics*

Statistical analyses to compare participant demographics were carried out using GraphPad Prism 8 software (Graphpad Software, San Diego, CA, USA). For continuous measures, a Mann-Whitney U-test was used when comparing two groups and a Kruskal-Wallis test when comparing three groups. For non-continuous measures, the Chi-square test was used. P-values as <0.05 were considered significant.</p>

Molecular Degree of Perturbation (MDP) analysis was performed by R using *mdp* R package<sup>41</sup>, and differences between the mean ranks of the groups were assessed by Mann-Whitney U test followed by Benjamini-Hochberg False discovery correction.<sup>40</sup> Cell population estimates were calculated using the cellCODE<sup>42</sup> R package, with the IRIS<sup>43</sup> and DMAP<sup>44</sup> data sets used as a reference. Modular analysis was performed using the R package tmod<sup>45</sup> and its HGtest method, with DEGs used as the foreground and all genes used as the background signal.

Differential expression analysis (DEA) was performed in R using the MaSigPro package<sup>46</sup> to characterise longitudinal differential gene expression of genes measured by RNA-Seq: this followed a two-step regression method, finding genes with significant temporal expression changes and also significant differences between clinical groups. A quadratic regression model was executed due to the number of timepoints analysed. The regression model treats time as a quantitative variable so differentially expressed are not only detected, but also changes in trends and magnitude.

Longitudinal DEA of genes measured by dcRT-MLPA was assessed by means of linear mixed models for repeated measures over time using lme4 package in R.<sup>47</sup> A Benjamini-Hochberg False discovery correction was performed, with an adjusted p-value of <0.05 deemed significant. Non-parametric Mann-Whitney U-test followed by Benjamini-Hochberg correction was performed to identify DEGs between patients who had a good and poor treatment outcome. Correlations were evaluated using Pearson's correlation coefficient.

Treatment outcome signatures based on dcRT-MLPA data were identified in TB patients of South Africa and Indonesia using Recursive Feature Elimination  $(RFE)^{48}$  and Random Forest (RF). Because the number of patients with a good treatment outcome was considerably larger than those with a poor treatment outcome (poor, n=38; good, n=134), a random down-sampling technique as well as a Synthetic Minority Oversampling Technique

221	(SMOTE) were applied to balance the classes (i.e. "good treatment outcome" and "poor
222	treatment outcome") of the dataset. <sup>49</sup> RF was performed as machine learning algorithm on the
223	dataset including the selected genes and the performance of gene signatures was evaluated by
224	Leave-One-Out Cross Validation (LOOCV). <sup>50,51</sup> We assessed the classifying performance of
225	the model by evaluating Receiver Operating Characteristic (ROC) curve and Area Under the
226	ROC Curve (AUC) with 95% Confidence Interval (CI). An extended description of the data-
227	analysis methods is provided in the Supplementary Information.
228	
229	<u>Role of Funders</u>
230	Funders had no role in study design, data collection, data analyses, data interpretation, writing

of the report and decision to submit the paper for publication.

232

#### 233 **Results**

#### 234 <u>Study Design and Cohort</u>

Pulmonary TB patients were recruited into the prospective longitudinal study in South Africa 235 and Indonesia, and followed up through standard treatment and for the following 12 months. 236 Altogether, 39 TB patients of the 176 recruited had a "poor treatment outcome", with 7 237 patients dying, 26 failing treatment (based on continued sputum smear or culture positivity at 238 239 month 6), and 6 experiencing recurrences in the subsequent 18 months. The "poor treatment outcome" rates were similar in the two sites (Table 1). The median age of the patients was 240 equal in patients with either a good or poor treatment outcome (median = 47 years), with a 241 higher proportion of males with a poor treatment outcome than a good treatment outcome (56% 242 and 67% respectively). The proportion of TB patients with DM with a poor treatment outcome 243 (15/39; 38%) was slightly higher than that with a good treatment outcome (44/137; 32%), 244

whereas the proportion with TBrel-IH was higher in those with a good treatment outcome
(65/137; 47%) than a poor treatment outcome (14/39; 36%). There was no evidence that those
who had a poor treatment outcome had more severe TB at diagnosis, with similar sputum
bacterial loads (as measured by TTP) in TB patients from South Africa and similar sputum
smear grade in Indonesia across the good and poor treatment outcome groups.

### 250 *Poor treatment outcome was reflected by an attenuated treatment response compared to good*

#### 251 *treatment outcome*

The holistic unbiased analysis of gene expression in TB patients with good or poor treatment 252 outcomes by RNA-Seq approach was performed on a subset of study participants (Table 1). 253 There were significant changes in global gene expression in patients with a good treatment 254 outcome continuously through TB treatment, reflecting treatment response (Figure 1A). Gene 255 expression perturbation was also evident in patients who had a poor treatment outcome, 256 although the sample score was higher at diagnosis compared to patients who had a good 257 258 treatment outcome. This represents differences at the transcriptomic level between patients with a good versus a poor treatment outcome, already before initiation of anti-TB treatment. 259 This was followed by less change over time in response to TB treatment in the poor TB 260 outcome group. 261

Next, we focused our molecular distance analysis on 144 TB-associated genes as 262 measured by dcRT-MLPA, which was performed on all study participants (n=201) (Table 1). 263 Again, there were significant changes in global gene expression continuously through TB 264 treatment in patients with a good treatment outcome, but not in patients with a poor treatment 265 266 outcome (Figure 1B), reflecting an attenuated TB treatment response. Despite the substantial treatment response in patients who had a good treatment outcome, gene expression perturbation 267 did not completely normalize to levels of healthy controls by 6 months (Supplementary Figure 268 269 S1).

Together, these data suggest that there was a different biosignature in those with good versus poor treatment outcomes, which was reflected by transcriptomic differences before initiation of anti-TB treatment and by a tempered response to anti-TB treatment in patients with a poor treatment outcome compared to patients with a good treatment outcome.

#### 274 <u>Global Differential expression in patients who had good or poor responses to TB treatment</u>

The changes in gene expression in the RNA-Seq data through time and between the patients 275 276 with a good or poor treatment outcome were analyzed by MaSigPro, initially in the South African and Indonesian cohorts separately. The strength in this method was that it was able to 277 monitor the change in dynamics over time and also between different treatment groups. In 278 279 South Africa, the genes which changed differently through time between the patients with good 280 or poor treatment outcome were grouped into nine clusters (Supplementary Figure S2A, Supplementary Table S2), with an increase in expression through treatment in four clusters 281 282 (1,2,3,5), a decrease in four clusters (4,6,7,8), and no change in one cluster (9). Genes with higher expression throughout treatment in TB patients with poor treatment outcome were 283 grouped in seven clusters (1,3,4,5,7,8,9) and those with higher expression in TB patients with 284 a good treatment outcome were grouped in two clusters (2,6). A similar pattern was observed 285 286 in the Indonesian cohort, with DEGs identified through treatment between good and poor 287 separating into nine clusters (genes increasing in clusters 2,5,7, and decreasing in clusters 1,3,4,6,8,9) (Supplementary Figure S2B, Supplementary Table S3), with higher expression in 288 either the good or poor treatment outcome group. Importantly, these differences in gene 289 290 expression through time were observed in all TB patient groups, irrespective of their DM status.

The genes grouped into the clusters in the Indonesian and South African cohorts partially overlapped but there was variability. A third MaSigPro analysis was therefore conducted, to find those genes which were differentially expressed through treatment between TB patients with a good or poor treatment outcome, irrespective of their geographical origin

(Figure 2, Supplementary Table S4). Again, the genes differentially expressed through treatment in the combined analysis separated into nine clusters, with variable patterns of expression over time and between TB patients with good or poor treatment outcome. Some clusters (2,5,6) contained genes which were different between the groups at all time points, whereas other clusters (1,3,4,5,7,8,9) were similar at some timepoints and more divergent at others (Figure 2, Table 2).

301 The number of transcripts within each cluster in the combined analysis ranged from 4 to 47 (Table 2), with the majority of genes identified in all clusters encoding proteins. There 302 303 were also various regulatory transcripts in some clusters, including long non-coding RNAs, miRNA, snoRNA, retained introns, as well as antisense, nonsense-mediated decay, 304 overlapping senses and sense intronic transcripts. To understand the biological function of the 305 306 DEGs, the transcripts within each cluster were analysed using the g:COST tool within the g:Profiler application<sup>52</sup>, to determine significant enrichment of genes in Gene Ontology (GO) 307 molecular function, cellular component and biological process categories, as well as in curated 308 biological pathways from KEGG and Reactome databases and the CORUM protein database. 309 Genes in cluster 2 were largely involved in B cell receptor signalling, seen in the GO and 310 pathway analyses, and these were more highly expressed in people who had a poor treatment 311 outcome, with increasing expression through treatment. This upregulation of genes involved in 312 313 B cell function, particularly those involved in earlier stages of B cell development, was not 314 related to the overall number of B cells in the samples, as predicted from the samples using CellCode analysis package (Supplementary Figure S3). Cluster 9 was predominantly 315 composed of immunoglobulin transcripts, whose expression decreased much more 316 317 substantially in patients with a good treatment outcome. The largest gene cluster (4) was enriched with genes involved in actin remodelling, including the Arp 2/3 complex, and in 318 pathways related to infections with bacteria such as Shigella, E. coli, Yersinia and Salmonella. 319

320 Cluster 7 contained genes related to mitotic cell division, and these were more highly expressed in patients with a poor treatment outcome (Table 2). These analyses were also performed using 321 the DAVID online tool<sup>53</sup>, and similar results were obtained (not shown). The DEGs found in 322 the combined and separate cohort MaSigPro analyses were used as a foreground against all 323 genes in a modular analysis using the Tmod package, which gives biological function to a gene 324 list. It showed an upregulation of genes involved in B cell function in good versus poor 325 326 treatment outcomes, in both the Indonesian and South African cohorts (Supplementary Table S5). 327

#### 328 Identification of DEGs through TB treatment in patients with good or poor treatment

329 *outcomes* 

Next, we focused our DEA on 144 genes that previously have been associated with TB<sup>39</sup> using 330 dcRT-MLPA (Supplementary Table S6). No significant DEGs were detected by directly 331 332 comparing patients with a good versus a poor treatment outcome at the indicated timepoints (Supplementary Figure S4), and therefore we analyzed longitudinal expression of genes. 333 Kinetic profiling of DEGs identified 16 DEGs in patients with a good treatment outcome and 334 12 DEGs in patients with a poor treatment outcome. The longitudinal expression of DEGs 335 identified by dcRT-MLPA showed a significant correlation with genes measured by RNA-Seq. 336 337 highlighting the validity and reproducibility of our approach (Supplementary Figure S5). A high correlation between DEGs of patients who had a poor treatment outcome and DEGs of 338 patients who had a good treatment outcome could be detected (R=0.87, p<0.0001), 339 340 highlighting the challenge of discriminating patients with a good versus a poor treatment outcome based on single genes (Supplementary Figure S6). Genes associated with active 341 TB<sup>15,20,54</sup> or risk of developing TB<sup>22</sup> were substantially downregulated (*GBP1*, *GBP2*, *GBP5*, 342 and IFITM3) or upregulated (GNLY and PRF1) over time in TB patients regardless of their 343 treatment outcome, reflecting transcriptomic response to anti-TB treatment (Figure 3A and 344

Supplementary Figure S7). Other genes associated with active TB were significantly down- or 345 upregulated (STAT2, MMP9, IRF7, IFI6, IFIT2, IFIT3, and CCR7) during anti-TB treatment 346 in patients who had a good treatment outcome, but not in patients who had a poor treatment 347 outcome, or vice versa (CD3E, PTPRCv1, NLRP1, BCL2)<sup>15,39,54,55</sup>. The expression of TAGAP, 348 previously associated with active TB<sup>55</sup>, was significantly increased during anti-TB treatment 349 in patients who had a poor treatment outcome. Modular analysis showed that the gene profile 350 351 of regulated genes was dominated by genes in the interferon (IFN) signaling pathway, especially in patients who had a good treatment outcome (Figure 3B). 352

#### 353 *Identification of a signature predicting treatment outcome*

Machine learning algorithms were implemented on data obtained at each time point to develop 354 biomarker panels to predict treatment outcomes at different stages of TB treatment. First, we 355 aimed to identify gene signatures from RNA-Seq analysis on a subset of subjects, but we found 356 a low performance of gene signatures generated on diagnosis, week two and month six 357 358 (AUC=0.625, AUC=0.667 and AUC=0.615, respectively) to predict treatment outcome, 359 potentially due to a low number of patients in the training and test set (Supplementary Figure S8A). The best performing model was built on month two resulting in an AUC of 0.8667 360 361 (Supplementary Figure S8A, Supplementary Table S7). We also tested an active TB disease biomarker signature, namely the three-gene Sweeney signature<sup>20</sup>, to determine whether it 362 resolved significantly more in those with a good treatment outcome than in those with a poor 363 treatment outcome. This signature has previously been shown to persist in patients with 364 persistent lung inflammation<sup>26</sup>. However, in our RNA-Seq data, this signature revealed an AUC 365 366 of 0.5333 (Supplementary Figure S8B) highlighting that the process behind poor treatment outcome cannot be predicted by expression of these three genes. 367

368 Next, we aimed to identify early correlates of treatment outcome by implementing 369 machine learning algorithms on gene expression as measured by dcRT-MLPA. We focused

370 our analysis on the identification of gene predictors at diagnosis and at week two that could possibly be used in future studies to predict the occurrence of poor or good treatment outcome 371 before or early after anti-TB treatment initiation, first by down-sampling the good treatment 372 outcome class. The top eight ranked genes (GBP1, FCGR1A, STAT1, IFITM3, BCL2, CCL4, 373 TLR9, CD274) from the diagnosis signature were used for RF machine learning model 374 implementation (Table 3). Excitingly, the signature had a high predictive power (AUC=0.815) 375 376 to classify TB patients with a good or poor treatment outcome, already before anti-TB treatment initiation (Figure 4A). Furthermore, the gene signature showed high performance on the 377 378 cohorts separately (South Africa, AUC=0.845; Indonesia, AUC=0.744). Next, we investigated whether accuracy could be improved by predicting treatment outcome after initiation of anti-379 TB treatment, thus measuring the early treatment response. We identified a 22-gene signature 380 to predict treatment outcome at two weeks after initiation of anti-TB treatment (Table 3). The 381 performance of the week two signature in predicting treatment outcome was slightly improved 382 (AUC=0.834) compared to the diagnosis signature, especially in patients from the Indonesian 383 cohort (AUC=0.867 versus AUC=0.744 at diagnosis). Furthermore, we identified a 14-gene 384 month two signature, which, however, demonstrated a slightly lower accuracy in predicting 385 treatment outcome compared to diagnosis and week two gene signatures (AUC=0.791). 386

Since we detected differences in the kinetics of gene expression of patients who had a 387 good treatment outcome versus patients with a poor treatment outcome (Figure 1), we next 388 389 assessed whether a "delta" gene signature, by subtracting week two values from diagnosis, could improve the predictive performance. The delta signature encompassed seven genes 390 (GNLY, MRC1, GBP5, NLRP1, FLCN1, ZNF532, and IFIT2) and slightly improved predictive 391 392 performance (pooled cohorts, AUC=0.849; South Africa, AUC=0.839 and Indonesia, AUC=0.872) compared to the week two and diagnosis signatures (Supplementary Figure S9, 393 Supplementary Table S8). Multiple genes were included in more than one gene signature 394

(Supplementary Figure S10A), of which four genes (GBP1, GBP5, FCGR1A, INDO) are 395 shown in Figure 4B. Next, we validated performance of the diagnosis signature and month two 396 signature on an independent validation cohort<sup>28</sup>, which like our cohorts, included diabetic 397 patients. Our diagnosis gene signature had high predictive power on the Indian validation 398 cohort (AUC=0.749) (Figure 4C). The week two and delta signatures could not be validated 399 on the Indian cohort, because samples were not collected two weeks after initiation of anti-TB 400 401 treatment in this cohort. Three genes (CD3E, PTPRCv1, NOD2) that were included in our gene signatures, were also part of gene signatures described by Sivakumaran et al. (Supplementary 402 403 Figure S10B). Finally, we assessed whether gene signatures with improved performance could be obtained by applying  $\text{SMOTE}^{49}$  as an alternative sampling technique. A diagnosis  $\text{SMOTE}^{49}$ 404 gene signature was obtained that showed overlap with the diagnosis gene signatures obtained 405 406 by random down-sampling (Supplementary Table S9, Supplementary Figure S10C). The 407 SMOTE signature produced a high degree of accuracy in discriminating patients with a good treatment outcome from patients with a poor treatment outcome, but performed with lower 408 409 accuracy compared to the diagnosis signature obtained by random down-sampling (pooled cohorts, AUC=0.728; South Africa, AUC=0.695; Indonesia, AUC=0.765) (Supplementary 410 Figure S11). The diagnosis SMOTE signature exerted a similar predictive capacity on the 411 external Indian cohort compared to the down-sampling signature (SMOTE, AUC=0.704; 412 413 down-sampling, AUC=0.749).

Taken together, we identified gene signatures with high predictive power on treatment outcome, irrespective of DM as comorbidity, in patients from South Africa and Indonesia and in patients from the external Indian validation cohort.

417

#### 418 **Discussion**

In this study, we identified peripheral blood transcriptional signatures which predict anti-TB treatment success and failure in TB patients with or without concomitant hyperglycaemia or DM. Previous studies developing biomarker signatures of TB treatment success, recurrence or failure<sup>24-26,56</sup> did not include people with DM comorbidity, and we have previously found concomitant DM impairs existing TB diagnosis signature accuracy.<sup>32</sup> Here we showed DM also affects existing TB treatment-response biomarker signatures in the RNA-Seq dataset, suggesting that they should be derived with cohorts including this population.

Our whole cohort dataset, from which we generated treatment outcome signatures, was 426 derived using our dcRT-MLPA gene set, which did not contain most of the genes reported in 427 previous signatures, except GBP5, which was included in our week two and month two gene 428 signatures. Sivakumaran et al.<sup>28</sup> recently reported baseline and month two gene signatures 429 predicting treatment outcome at six months after initiation of anti-TB treatment, using the same 430 431 material (whole blood), technique (dcRT-MLPA) and gene set. Notably, our treatment outcome gene signatures showed some overlap with the signatures reported by Sivakumaran et al. 432 (CD3E, PTPRCv1, NOD2), suggesting that these genes are useful in predicting treatment 433 outcome independently of ethnical background. Furthermore, our treatment outcome gene 434 signatures showed overlap of genes of the TB risk signature predicting TB progression from 435 healthy controls more than a year before onset of TB (GBP1, GBP2, GBP5, FCGR1A, STAT1, 436 TAP1).<sup>22</sup> Within our study, 12 genes (BCL2, BMP6, CCL13, CD209, FCGR1A, GBP1, GBP5, 437 INDO, MMP9, MRC1, STAT1, TLR9) were overlapping between gene signatures, including 438 both the gene signatures obtained by down-sampling and the gene signatures obtained by 439 SMOTE. The occurrence of genes in multiple gene signatures within this study and between 440 studies highlights the power of transcriptomic biomarkers in predicting treatment outcome and 441

suggests that universal biomarkers can be applied to cohorts of different ethnicity andindependently of the DM/glycaemia status of TB patients.

Patients with a poor treatment outcome responded to anti-TB treatment at the level of 444 individual genes, as detected by downregulation of genes (GBP1, GBP2, GBP5, IFITM3) that 445 have been associated with active TB and upregulation of genes (CD3E, PTPRCv1, NLRP1, 446 GNLY, PRF1, BCL2) that show lower expression in patients with active TB compared to LTBI 447 or healthy controls<sup>15,20,39,55</sup>. However, MDP analysis showed that the response to anti-TB 448 treatment was diminished in those with a poor treatment outcome compared to patients who 449 450 had a good treatment outcome. Notably, the majority of genes that were significantly downregulated in patients who had a good treatment outcome, but not in patients who had a 451 poor treatment outcome, are involved in IFN signaling (IRF7, IFIT2, IFIT3, STAT2, IFI6, 452 *TAP2*). This suggests that a poor treatment outcome was reflected by persisting IFN signaling 453 response and supports a role for type I IFN signaling in TB pathogenesis.<sup>15,57</sup> 454

TAGAP was significantly increased in patients who had a poor treatment outcome in 455 the pooled South African and Indonesian cohort as well as in both cohorts separately. TAGAP 456 encodes T-cell activation Rho-GTPase-activating protein, however, the exact role of TAGAP 457 in *Mtb* pathogenesis is currently unknown. Several studies have linked *TAGAP* with active TB; 458 TAGAP was enriched for differential acetylation peaks upon Mtb infection in granulocytes<sup>58</sup> 459 and TAGAP was induced upon vaccination with AERAS-402 vaccine encoding a fusion protein 460 of *Mtb* antigens.<sup>59</sup> Furthermore, *TAGAP* had higher expression in TB patients compared to 461 LTBI and healthy controls<sup>55</sup> and, surprisingly, lower expression in pulmonary TB compared to 462 household controls.<sup>60</sup> Our data showing that TAGAP expression was significantly increased 463 during anti-TB treatment in patients who had a poor treatment outcome could indicate that 464 TAGAP is actively involved in TB pathogenesis or that TAGAP expression is a consequence of 465 persisting *Mtb* infection, but this remains to be investigated. 466

There are several limitations of the current study. First, the sample size in this study 467 was not based on an a priori power calculation, as this study was part of a larger study 468 investigating differences in gene expression in patients with varying degrees of hyperglycemia. 469 470 To increase statistical power, we therefore pooled patients from two cohorts (South Africa and Indonesia), which introduced heterogeneity within the studied groups. However, this can also 471 be a strength, potentially increasing application over different ethnic backgrounds. Second, 472 473 there were missing values in the cohort study. The missing values occurred as a result of random drop-outs or technical errors caused by low quantity or quality of some samples, and 474 475 therefore the use of linear mixed models for the DEA most likely produced unbiased results. Third, although the prevalence of hyperglycaemia/DM is not indicated in the majority of other 476 TB biomarker studies, which is a limitation of these studies considering the rising incidence of 477 478 TB-DM comorbidity, our study contained many patients with high HbAc1 levels. Although this may have introduced a bias, the strength of this approach is that treatment outcome 479 signatures have been developed that can be applied to patients independently of their 480 glycaemia/DM status. Furthermore, we showed that our eight-gene diagnosis signature had a 481 high performance (AUC=0.749) when tested on an external validation cohort in patients with 482 a different ethnic background (India), which is striking since geographic or ethnic variations 483 may significantly impact on the immune responses to TB. 484

In this study, we demonstrated the potential of gene signatures to predict treatment outcome, in a cohort including patients with concomitant DM or hyperglycaemia. Identification of a diagnosis gene signature containing only eight genes in this study, and even fewer genes in signatures reported by others<sup>26,27</sup>, indicates that clinically-implementable biomarker signatures can be developed using transcriptomic-based approaches using easily accessible whole blood, and that are promising as surrogate marker for sputum culture conversion.

491

#### 492 **Contributors**

Study concept and design: BA, RvC, RR, PCH, GW, SAJ, JAC, MCH, HMD, THMO, JMC; 493 494 Patient recruitment, Sample collection, processing and selection: BA, KR, STM, LK, PCH, curation, 495 KS. RR. GW; Clinical database design, maintenance: SK-B, JAC; Laboratory Experiments and data acquisition: CE, SvV, JSL, JMC; Data Analysis and 496 interpretation: CLRvD, CE, SvV, VK, SAJ, CW, MCH, HMD, THMO, EV, JMC; Writing the 497 manuscript: CLRvD, CE, SAJ, HMD, THMO, EV, JMC; Critical Revision of the manuscript: 498 CLRvD, CE, KR, STM, SAJ, PCH, JAC, MCH, HMD, THMO, EV, JMC; All authors read 499 and approved the final version of the manuscript. 500

### 501 **Declaration of Interests**

502 GW had patents to methods of tuberculosis diagnosis and to tuberculosis biomarkers unrelated 503 to the current study. The rest of the authors declare no financial or commercial conflicts of 504 interest.

#### 505 Acknowledgements

participants involved in 506 The authors acknowledge all study. The this authors acknowledge Bahram Sanjabi, Desiree Brandenburg-Weening, and Pieter van der Vlies for 507 the RNA-Seq, Evelien Temminck for providing technical 508 assistance with assistance with dcRT-MLPA experiments, Erni Durdevic for providing statistical and machine 509 learning advice, and Prof. Dr. Harleen Grewal and Dr. Dhanasekaran Sivakumaran for 510 providing datafiles of the cross-validation dataset. 511

#### 512 **Data Sharing Statement**

513 RNA sequence data have been submitted to NCBI Gene Expression Omnibus (GEO) under

accession number GSE193979. dcRT-MLPA data can be found in Supplementary Table S6.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.08.22269796; this version posted February 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

## perpetuity. It is made available under a CC-BY-ND 4.0 International license .

#### **References** 515

World Health Organization. Global tuberculosis report 2021. Geneva: World Health 516 1. 517 Organization. Licence: CC BY-NC-SA 3.0 IGO., 2021. 518 2. Alemu MA, Yesuf A, Girma F, et al. Impact of HIV-AIDS on tuberculosis treatment outcome 519 in Southern Ethiopia-A retrospective cohort study. Journal of Clinical Tuberculosis and Other 520 Mycobacterial Diseases 2021; 25: 100279. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on 521 3. tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung 522 523 Dis 2019; 23(7): 783-96. 524 Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic 4. 525 review of 13 observational studies. PLoS med 2008; 5(7): e152. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment 526 5. 527 outcomes: a systematic review. BMC medicine 2011; 9(1): 1-15. 528 Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on 6. 529 treatment outcomes of patients with active tuberculosis. The American journal of tropical medicine 530 hygiene 2009; 80(4): 634. 531 Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the 7. 532 presentation and treatment response of pulmonary tuberculosis. Clinical Infectious Diseases 2007; 533 **45**(4): 428-35. Tuomilehto J. The emerging global epidemic of type 1 diabetes. Current diabetes reports 534 8. 535 2013; **13**(6): 795-804. 536 Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 9. 537 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice 2019; 157: 107843. 538 539 10. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for 540 predicting outcome: systematic review and meta-analysis. The Lancet infectious diseases 2010; 10(6): 387-94. 541 Bhat J, Rao V, Muniyandi M, Yadav R, Karforma C, Luke C. Impact of sputum quality and 542 11. 543 quantity on smear and culture positivity: findings from a tuberculosis prevalence study in central 544 India. Transactions of the Royal Society of Tropical Medicine Hygiene 2014; 108(1): 55-6. 545 Hernández P, Punchak M, Camacho M, Hepple P, McNerney R. Investigating the quality of 12. 546 expectorated sputum for tuberculosis diagnosis in Bolivia. The International Journal of Tuberculosis 547 and Lung Disease 2015; 19(9): 1065-7. 548 Meyer AJ, Atuheire C, Worodria W, et al. Sputum quality and diagnostic performance of 13. 549 GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. PLoS One 550 2017; **12**(7): e0180572. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis 551 14. 552 diagnosis: A systematic comparison of 16 signatures. *PLoS medicine* 2019; **16**(4): e1002786. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood 553 15. 554 transcriptional signature in human tuberculosis. *Nature* 2010; **466**(7309): 973-7. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are 555 16. present after two weeks of antituberculosis therapy. PloS one 2012; 7(10): e46191. 556 Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern 17. 557 558 through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013; 559 207(1): 18-29. 560 Kaforou M, Wright VJ, Oni T, et al. Detection of tuberculosis in HIV-infected and-uninfected 18. 561 African adults using whole blood RNA expression signatures: a case-control study. PLoS Med 2013; 562 10(10): e1001538. 563 19. Maertzdorf J, McEwen G, Weiner 3rd J, et al. Concise gene signature for point-of-care 564 classification of tuberculosis. EMBO molecular medicine 2016; 8(2): 86-95. 565 20. Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. The Lancet Respiratory Medicine 2016; 4(3): 213-24. 566

medRxiv preprint doi: https://doi.org/10.1101/2022.02.08.22269796; this version posted February 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Scriba TJ, Penn-Nicholson A, Shankar S, et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. *PLoS Pathog* 2017; **13**(11):

risk: a prospective cohort study. The Lancet 2016; 387(10035): 2312-22.

Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease

567

568 569

570

571

21.

22.

e1006687.

Mistry R, Cliff JM, Clayton CL, et al. Gene-expression patterns in whole blood identify 572 23. 573 subjects at risk for recurrent tuberculosis. J Infect Dis 2007; 195(3): 357-65. 574 24. Cliff JM, Cho J-E, Lee J-S, et al. Excessive cytolytic responses predict tuberculosis relapse 575 after apparently successful treatment. The Journal of infectious diseases 2016; 213(3): 485-95. Thompson EG, Du Y, Malherbe ST, et al. Host blood RNA signatures predict the outcome of 576 25. 577 tuberculosis treatment. Tuberculosis 2017; 107: 48-58. 578 26. Warsinske HC, Rao AM, Moreira FM, et al. Assessment of validity of a blood-based 3-gene 579 signature score for progression and diagnosis of tuberculosis, disease severity, and treatment response. 580 JAMA network ope 2018; 1(6): e183779-e. 581 27. Suliman S, Thompson EG, Sutherland J, et al. Four-gene pan-African blood signature predicts 582 progression to tuberculosis. American journal of respiratory and critical care medicine 2018; 197(9): 583 1198-208. 584 Sivakumaran D, Jenum S, Vaz M, et al. Combining host-derived biomarkers with patient 28. 585 characteristics improves signature performance in predicting tuberculosis treatment outcomes. 586 Communications Biology 2020; 3(1): 359. Ugarte-Gil C, Alisjahbana B, Ronacher K, et al. Diabetes mellitus among pulmonary 587 29. 588 tuberculosis patients from 4 tuberculosis-endemic countries: the TANDEM study. Clinical Infectious 589 Diseases 2020; 70(5): 780-8. 590 Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-30. 591 diabetes and associated risk factors among tuberculosis patients in India. PLoS One 2012; 7(7): 592 e41367. 593 Restrepo BI, Camerlin AJ, Rahbar MH, et al. Cross-sectional assessment reveals high 31. 594 diabetes prevalence among newly-diagnosed tuberculosis cases. Bulletin of the World Health 595 Organization 2011; 89: 352-9. 596 Eckold C, Kumar V, Weiner J, et al. Impact of Intermediate Hyperglycemia and Diabetes on 32. 597 Immune Dysfunction in Tuberculosis. Clinical Infectious Diseases 2021; 72(1): 69-78. 598 Prada-Medina CA, Fukutani KF, Kumar NP, et al. Systems immunology of diabetes-33. 599 tuberculosis comorbidity reveals signatures of disease complications. Scientific reports 2017; 7(1): 1-600 16. Ruslami R, Koesoemadinata RC, Soetedjo NNM, et al. The effect of a structured clinical 601 34. 602 algorithm on glycemic control in patients with combined tuberculosis and diabetes in Indonesia: A randomized trial. Diabetes Research and Clinical Practice 2021; 173: 108701. 603 604 35. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. 605 Bioinformatics 2013; 29(1): 15-21. 606 Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. 36. 607 http://www.bioinformatics.babraham.ac.uk/projects/fastqc2020). 608 37. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput 609 sequencing data. bioinformatics 2015; 31(2): 166-9. 610 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-38. 611 seq data with DESeq2. Genome biology 2014; 15(12): 1-21. 612 39. Joosten S, Goeman J, Sutherland J, et al. Identification of biomarkers for tuberculosis disease 613 using a novel dual-color RT-MLPA assay. Genes & Immunity 2012; 13(1): 71-82. 614 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful 40. 615 approach to multiple testing. Journal of the Royal statistical society: series B (Methodological) 1995; 57(1): 289-300. 616 617 Lever M RP, Nakaya H. mdp: Molecular Degree of Perturbation calculates scores for 41. 618 transcriptome data samples based on their perturbation from controls. R package version 1.12.0. 2021. 619 https://mdp.sysbio.tools/. 24 medRxiv preprint doi: https://doi.org/10.1101/2022.02.08.22269796; this version posted February 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

### perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 620 42. Chikina M, Zaslavsky E, Sealfon SC. CellCODE: a robust latent variable approach to differential expression analysis for heterogeneous cell populations. *Bioinformatics* 2015; **31**(10): 621 622 1584-91. 623 43. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood 624 microarray data identifies cellular activation patterns in systemic lupus erythematosus. *PloS one* 2009; **4**(7): e6098. 625 626 44. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional 627 circuits control cell states in human hematopoiesis. Cell 2011; 144(2): 296-309. 628 45. Weiner 3rd J, Domaszewska T. tmod: an R package for general and multivariate enrichment 629 analysis. PeerJ Preprints 2016; 4: e2420v1. 630 Nueda MJ, Tarazona S, Conesa A. Next maSigPro: updating maSigPro bioconductor package 46. 631 for RNA-seq time series. *Bioinformatics* 2014; **30**(18): 2598-602. 632 47. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. 633 arXiv preprint arXiv:14065823 2014. 634 48. Gregorutti B, Michel B, Saint-Pierre P. Correlation and variable importance in random 635 forests. Statistics and Computing 2017; 27(3): 659-78. 636 49. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority oversampling technique. Journal of artificial intelligence research 2002; 16: 321-57. 637 638 50. Liaw A, Wiener M. Classification and regression by randomForest. *R news* 2002; 2(3): 18-22. 639 Kuhn M. Building predictive models in R using the caret package. Journal of statistical 51. software 2008; 28(1): 1-26. 640 641 Raudvere U, Kolberg L, Kuzmin I, et al. g:Profiler: a web server for functional enrichment 52. 642 analysis and conversions of gene lists (2019 update). Nucleic Acids Research 2019; 47(W1): W191-643 W8. 644 53. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the 645 comprehensive functional analysis of large gene lists. *Nucleic acids research* 2009; **37**(1): 1-13. Gebremicael G, Kassa D, Quinten E, et al. Host gene expression kinetics during treatment of 646 54. 647 tuberculosis in HIV-coinfected individuals is independent of highly active antiretroviral therapy. The 648 Journal of infectious diseases 2018; 218(11): 1833-46. 649 55. Gebremicael G, Kassa D, Alemayehu Y, et al. Gene expression profiles classifying clinical 650 stages of tuberculosis and monitoring treatment responses in Ethiopian HIV-negative and HIV-651 positive cohorts. PLoS One 2019; 14(12): e0226137. 652 56. Heyckendorf J, Marwitz S, Reimann M, et al. Prediction of anti-tuberculosis treatment 653 duration based on a 22-gene transcriptomic model. European respiratory journal 2021. Moreira-Teixeira L, Mayer-Barber K, Sher A, O'Garra AJJoEM. Type I interferons in 654 57. 655 tuberculosis: Foe and occasionally friend. J Journal of Experimental Medicine 2018; 215(5): 1273-85. del Rosario RCH, Poschmann J, Kumar P, et al. Histone acetylome-wide association study of 656 58. 657 tuberculosis. bioRxiv 2019: 644112. Sivakumaran D, Blatner G, Bakken R, et al. A 2-Dose AERAS-402 Regimen Boosts CD8+ 658 59. 659 Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients. Frontiers in Immunology 2021; 12:
- 2141. 660
- 60. Sivakumaran D, Ritz C, Giøen JE, et al. Host blood RNA transcript and protein signatures for 661 662 sputum-independent diagnostics of tuberculosis in adults. Frontiers in immunology 2020; 11: 3795.
- 663

#### **Tables** 664

#### **Table 1. Study Participant Demographics** 665

Characteristic	Country	TB Pa	atients		P-value
		Good Outcome	Poor Outcome	Healthy Controls	
	S Africa	76	18	27	-
Total Number of Participants	Indonesia	61	21	0	-
	All	137	39	27	-
	S Africa	46 (22-68)	42 (19-55)	42 (30-70)	0.485
Age in years, median (range)	Indonesia	49 (25-73)	49 (35-68)	-	0.96
	All	47 (22-73)	47 (19-68)	42 (30-70)	0.2801
	S Africa	58 (44/32)	67 (12/6)	52 (14/13)	0.6981
Sex, % male (No. male/ female)	Indonesia	53 (32/29)	67(14/7)	-	0.3136
	All	56 (76/61)	67 (26/13)	52 (14/13)	0.2704
Number with Diabetes / Intermediate	S Africa	13/49/14	4/11/3	0/0/27	$0.8775^{\$}$
Hyperglycaemia / Normal glycaemia	Indonesia	31/16/14	11/3/6	-	0.5589
(%)	All	44/65/28	15/14/9	0/0/27	0.5409 <sup>\$</sup>
	S Africa	6.0 (4.9-14.3)	6.0 (4.8-14.1)	5.3 (4.8-6.4)	0.6144\$
HbA1c median (range)	Indonesia	8.15 (4.9-17.1)	7.1 (5.1-14.1)	-	0.5612
-	All	6.0 (4.9-17.1)	6.1 (4.8-14.1)	5.3 (4.8-6.4)	0.9892 <sup>\$</sup>
	S Africa	18.7 (13.9-32.3)	18.3 (13.7-31.2)	23.7 (17.4-45.2)	0.9588 <sup>\$</sup>
BMI at TB diagnosis:, median (range)	Indonesia	19.7 (13.8-33.3)	18.8 (16.3-27.3)	-	0.8433
	All	19.1 (13.8-33.3)	18.8 (13.7-31.2)	23.7 (17.4-45.2)	0.8351 <sup>\$</sup>
TTP (days) at TB diagnosis: Median (range) (missing values)	S Africa	6 (1-21) (18)	6 (3-21) (3)	N/A	0.8916
Smear Grade at diagnosis number: 3+/2+/1+/scanty/negative	Indonesia	16/23/14/2/6	8/4/6/2/1	N/A	0.3637
	S Africa	49/19 (8)	10/6 (2)	N/A	0.4518
Sputum conversion at Month 2: number yes/no (missing values)	Indonesia	44/15 (2)	10/8 (2)	N/A	0.1227
yes/no (missing values)	All	93/34 (10)	20/14 (4)	N/A	0.1029
Outcome classification: Cured	S Africa	76/0/0/0	0/4/10/4	N/A	< 0.0001
/Recurrence/Failed/Died	Indonesia	61/0/0/0	0/2/16/3	N/A	< 0.0001
/Recurrence/Failed/Died	All	137/0/0/0	0/6/26/7	N/A	<0.0001
	S Africa	26	6	0	-
RNASeq subset	Indonesia	23	8	0	-
	All	49	14	0	-
	S Africa	76	18	27	-
MLPA subset	Indonesia	58	21	0	-
	All	135	39	27	-

666

\$ Comparison of TB patients with Good or Poor TB treatment outcome, HC excluded

#### Table 2. Clusters of genes differentially expressed between TB patients with good or poor treatment 667

#### outcomes to TB treatment in MaSigPro analysis of combined RNA-Seq data from South Africa and 668

669 Indonesia

Clus ter	Overall pattern	Num ber of	Gene Function				<b>Top Functions from g:Profiler**</b> with adjusted P<0.05
Nu mbe r		gene trans cripts	Protei n Codin g	Proce ssed Trans cript	Pseud o- gene	Regul -atory RNAs	
1	↓ through treatment; Higher in Good at W2	26	20	1	0	5	GO:MF – Opsonin Binding; GO:CC – Intracellular Vesicles; Endomembrane System
2	↑ through treatment; Higher in Poor throughout	14	13	0	0	1	GO:BP – B cell receptor (BCR) signaling; GO:CC – BCR complex KEGG – BCR signaling; primary immunodeficiency; REAC – BCR signaling WP – BCR signaling CORUM – CIN85-BLNK complex
3	↑ through treatment; Higher in Good at W26	25	17	2	0	6	No significant results
4	↓ through treatment; Higher in Poor throughout	47	37	2	2	6	GO:CC – Arp2/3 complex; KEGG – Shigellosis; E.coli, Yersinia, Salmonella infection; Endocytosis; REAC – Ephrin signaling; Rho GTPAses activate WASPs and WAVEs; TF – ZNF544 CORUM – Arp2/3 complex
5	Small↓ through treatment; Higher in Poor throughout	11	6	1	1	3	GO:MF – L-tyrosine transmembrane transporter activity; GO:BP – positive regulation of fatty acid transport.
6	No change; Higher in Poor throughout	4	0	0	3	1	No significant results
7	$\uparrow \text{ to W2,} \\ \text{then } \downarrow; \\ \text{Higher in} \\ \text{Poor at W2}$	4	4	0	0	0	GO:BP – mitotic cell cycle process WP – Retinoblastoma Gene in Cancer
8	↑ in Good through treatment; No change in Poor	7	3	0	2	2	GO:MF - RNA polymerase III activity
9	↓ through treatment; Much greater change in Good	10	10	0	0	0	GO:MF – immunoglobulin receptor binding GO:BP – phagocytosis, recognition; complement activation, classical pathway; immunoglobulin mediated immune response; B cell activation GO:CC – immunoglobulin complex; E/C space; plasma membrane REAC – Classical antibody-mediated complement activation; FCGR activation; phagocytosis.

670 \*Retained introns, Antisense, LncRNA, miRNA, nonsense-mediated decay, sense overlapping, sense intronic,

671

snoRNA,

672 \*\*Redundant G:Profiler results are not shown

#### 673 Table 3. dcRT-MLPA Gene signatures Good versus Poor obtained by pooling the study groups and the cohorts

### 674

675

Diagnosis Signa	ature
Gene	Module
GBP1	IFN signaling genes
FCGR1A	IFN signaling genes
STAT1	IFN signaling genes
IFITM3	IFN signaling genes
BCL2	Apoptosis - Survival
CCL4	Treg associated genes
TLR9	Pattern recognition receptors
CD274	IFN signaling genes

Week two Signature					
Gene	Module				
GBP5	IFN signaling genes				
INDO	IFN signaling genes				
GBP1	IFN signaling genes				
BMP6	Cell growth - proliferation				
CXCL9	Chemokines				
GATA3	Th2 associated genes				
FCGR1A	IFN signaling genes				
MMP9	Inflammation				
PTPRCv1	T cell subset markers				
SPP1	Inflammation				
CD3E	T cell subset markers				
ASAP1	Small GTPases - (Rho) GTPase activating proteins				
IL5	Th2 associated genes				
TNFRSF1B	Apoptosis - Survival				
NLRP2	Inflammasome components				
MRC1	Pattern recognition receptors				
NLRP6	Inflammasome components				
IL22RA1	Th17 associated genes				
VEGF	Cell growth - proliferation				
KIF1B	Intracellular transport				
CCL19	Chemokines				
CD209	Pattern recognition receptors				

#### Month 2 Signature

Month 2 Signature				
Gene	Module			
BLR1	G protein-coupled receptors			
BMP6	Cell growth - proliferation			
CCL13	Chemokines			
GBP1	IFN signaling genes			
GBP2	IFN signaling genes			
GBP5	IFN signaling genes			
IFI16	IFN signaling genes			
IL9	Th9 associated genes			
INDO	IFN signaling genes			
MMP9	Inflammation			
NOD2	Pattern recognition receptors			
OAS3	IFN signaling genes			
PTPRCv2	T cell subset markers			
TAP1	IFN signaling genes			

Genes that appeared in more than one gene signature (diagnosis, week two or month two) are shown in bold. Gene signatures were obtained by down-sampling the majority class (good treatment outcome).


#### **Figure legends** 677

678 Figure 1. MDP plots representing the change in gene expression perturbation in TB patients categorized 679 based on treatment outcome. Full blood transcriptomes from TB patients who had a good or poor treatment 680 outcome were determined by (A) RNA-Seq and by (B) dcRT-MLPA. The extent of overall difference in gene 681 expression, relative to the median of expression at diagnosis in those who had a good treatment outcome, was 682 calculated for individual patients at the timepoints shown. The bars and whiskers show the median and data within 683 the  $Q_1$ -1.5 x inter quartile range (IQR) and  $Q_3$ +1.5 x IQR interval. Differences were significant by Mann-Whitney 684 U-test with Benjamini-Hochberg correction for multiple testing. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* 685 p<0.0001. 686

687 Figure 2. MaSigPro analysis of TB patients with good or poor treatment outcome, across combined South 688 African and Indonesian cohorts. Plots show hierarchical clusters of genes in patients with a good (blue) or poor 689 (red) treatment outcome. Bars show mean  $\pm 1$  SEM. Data were filtered to remove lowly abundant transcripts prior 690 to analysis. 691

692 Figure 3. DEA of all TB patients from the pooled (South African and Indonesian) cohorts categorized based 693 on treatment outcome compared to their gene expression levels at diagnosis. (A) Volcano plots representing 694 DEGs regulated during anti-TB treatment of TB patients who had a good treatment outcome (left panel) or a poor 695 treatment outcome (right panel). The y-axis scales of the plots are harmonized per treatment outcome.  $-\log_{10^{-1}}$ 696 transformed p-values are plotted against  $\log_2$  FC. Genes with p<0.05 and  $\log_2$  FC<-0.6 or >0.6 were labelled as 697 DEGs. (B) Heatmaps displaying  $\log_2 FC$  of the DEGs and corresponding gene modules. The saturation of color 698 represents the magnitude of differential expression. Differences were significant by means of linear mixed models. 699 \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001.

700 701 Figure 4. Prediction of treatment outcome in dcRT-MLPA data from peripheral blood. (A) ROC curves 702 showing the predictive power of the gene signatures identified in the balanced pooled cohort (South Africa and 703 Indonesia) to classify TB patients at diagnosis (left panel), two weeks (middle panel) or two months (right panel) 704 after initiation of anti-TB treatment into patients who had a good treatment outcome and patients who had a poor 705 treatment outcome, using the RFE-RF model and LOOCV. The dataset was balanced by down-sampling to 706 encompass the same number of individuals with poor and good treatment outcome (diagnosis, n=34; week two, 707 n=33; month two, n=34). (B) Gene expression kinetics of the single genes encompassing the diagnosis or week 708 two gene signatures predicting treatment outcome in the pooled cohort. Box plots depict GAPDH-normalized, 709 log<sub>2</sub>-transformed median gene expression values and the IQR, while the whiskers represent the data within the 710  $Q_1-1.5xIQR$  and  $Q_3+1.5xIQR$  interval. (C). ROC curves showing the predictive power of the gene signatures 711 identified in the balanced pooled cohort (South Africa and Indonesia) to classify TB patients from an external 712 validation cohort (India) at diagnosis (left panel) or two months (right panel) after initiation of anti-TB treatment 713 into patients who had a good treatment outcome and patients who had a poor treatment outcome. The dataset was 714 balanced by down-sampling to encompass the same number of individuals with poor and good treatment outcome 715 (diagnosis, n=22; month two, n=22). Abbreviations: AUC, area under the curve; CI, confidence interval.









Figure 2








Figure 4

### 714 Supplementary Information

#### 715 <u>Reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA)</u>

For each target-specific sequence, a specific RT primer was designed located immediately 716 downstream of the left- and right-hand half-probe target sequence. 125 ng RNA was reverse 717 718 transcribed to cDNA by incubation at 37°C for 15 min, using RT-primer mix and Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Promega, Leiden, The Netherlands). 719 Reverse transcriptase was inactivated by heating at 98°C for two minutes. The left- and right-720 hand half probes were hybridized to the cDNA at 60°C overnight and annealed half-probes 721 were ligated at 54°C for 15 minutes using ligase-65 (MRC-Holland). Ligase-65 was 722 subsequently inactivated by heating at 98°C for five minutes. Ligated probes were amplified 723 by PCR: 33 cycles at 95°C for 30 seconds, 58°C for 30 seconds and 72°C for 60 seconds, 724 followed by one cycle at 72°C for 20 minutes. PCR products were 1:10 diluted in Highly 725 726 deionized (Hi-Di) formamide (ThermoFisher) containing 400HD Rhodamine X (ROX) fluorophore size standard (ThermoFisher). PCR products were denatured at 95°C for five 727 minutes, stored immediately at 4°C and analyzed on an Applied Biosystems 3730 capillary 728 729 sequencer in GeneScan mode (BaseClear, Leiden, The Netherlands). Trace data were analyzed using GeneMapper software 5 (Applied Biosystems, Warrington, UK). The areas of each 730 assigned peak (arbitrary units) were exported for analysis in R (version 3.6.3). Data were 731 corrected for batch effect and normalized to housekeeping gene glyceraldehyde 3-phosphate 732 dehydrogenase (GAPDH). Signals below the threshold value for noise cutoff 733 734 in GeneMapper (log2 transformed peak area 7.64) were assigned the threshold value for noise cutoff. 735

RT primers and half-probes were designed by Leiden University Medical Centre
(LUMC, Leiden, The Netherlands) and comprised sequences for four housekeeping genes and

144 selected key immune-related genes to profile the following compartments of the human 738 immune response (Supplementary Table S1): (1) Adaptive immune responses: T-cell 739 responses; Th1 responses; Th2 responses; Th17/22 responses; Treg responses; T-cell 740 cytotoxicity; Immune cell subset markers including B-cells and NK-cells. (2) Innate immune 741 responses: Myeloid-associated markers and scavenger receptors; Pattern recognition receptors; 742 Inflammasome components. (3) Inflammatory and IFN-signalling genes. (4) Other genes: Anti-743 744 microbial activity; Apoptosis/cell survival; E3 ubiquitin protein ligases; Small GTPases/(Rho)GTPase activating proteins; Additional chemokines; Cell growth/proliferation; 745 746 Cell activation; Transcriptional regulators/activators; Intracellular transport; Mitochondrial Stress/Proteasome; Inflammation. 747

748

#### 749 *Linear Mixed Models for identification of DEGs*


Longitudinal DEGs were identified by means of linear mixed models using the lmer function of the lme4 package in R.<sup>47</sup> To increase statistical power, datasets of all TB patients included in the South African and Indonesian cohorts were pooled independent of diabetes/glycaemia status and split based on treatment outcome. Models were fitted on *GAPDH*-normalized log<sub>2</sub>transformed targeted gene expression data. Outcome-time interactions were included as fixed effects and the patients ID-time interactions were included as random effects.

756


#### 757 *Identification of gene signatures for treatment outcome*

For modelling analyses, RNA-Seq data were randomly split into training and test sets (60/40) using the R package *caret*.<sup>51</sup> Feature selection was performed for each timepoint using RFE<sup>48</sup> with repeated cross validation as the re-sampling method (n=10). A weighted model was fitted using glmnet method, using weights 1/frequency \* 0.5 and repeated cross validation for resampling (n=10). Each model was used to make predictions on the corresponding test set.

763 To identify signatures associated with treatment outcome in dcRT-MLPA data, TB patients of South Africa and Indonesia were pooled independent of diabetes/glycaemia status. 764 To balance the dataset, we applied two random sampling approaches using R: (1) a down-765 766 sampling approach, reducing the number of patients in the majority class (i.e. good treatment outcome) and (2) an up-sampling approach by generating synthetic data from existing data 767 using the SMOTE<sup>49</sup> function from the DMwR package in R, resulting in equal numbers of 768 patients in both classes. Then, RFE<sup>48</sup>, available in the *caret* R package<sup>51</sup>, was applied with K-769 fold validation (K=10) to the entire data set search for the optimal combination and number of 770 771 top-ranking genes able to separate TB patients with a good and poor treatment outcome. RFE is a powerful approach for variable selection in high-dimensional data by selecting features 772 that fit a model and removing the weakest feature (or features) until the specified number of 773 774 features is reached. Once the best predictors of treatment outcome were identified, the expression values of these genes were extracted from the dataset. We subsequently applied 775 RF<sup>50</sup> as machine learning algorithm on the dataset and evaluated the performance by LOOCV. 776 both available on the *caret* R package.<sup>51</sup> 777




Supplementary Figure S1. MDP plot representing the change in gene expression perturbation in TB patients from South Africa categorized based on treatment outcome. Blood transcriptomes from TB patients who had a good or poor treatment outcome were determined by dcRT-MLPA. The extent of overall difference in gene expression, relative to the median of expression in healthy controls, was calculated for individual patients at the timepoints shown. The bars and whiskers show the median and data within the Q1-1 $\cdot$ 5 x inter quartile range (IQR) and Q3+1 $\cdot$ 5 x IQR interval. Differences were significant by Mann-Whitney U-test with Benjamini-Hochberg correction for multiple testing. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001.




Supplementary Figure S2. Differential change in gene expression in TB patients through treatment in those who had a good or poor treatment outcome. MaSigPro analysis was conducted on the blood RNA-Seq data from TB patients from South Africa (a) or Indonesia (b), to identify genes which were significantly differentially expressed between those patients with a good or poor outcome. Plots show hierarchical clusters of genes, and bars show mean  $\pm 1$  SEM. Data were filtered to remove lowly abundant transcripts prior to analysis.






**Supplementary Figure S3.** Cell population estimates in good and poor treatment outcomes in South Africa and Indonesia. Estimates of relative differences in cell proportions were calculated from RNA-seq data using R package CellCODE. IRIS and DMAP data sets used as reference. Bars and whiskers show median and 1.5 x IQR.




Supplementary Figure S4. Differential expression analysis in patients from South Africa and Indonesia who had a poor treatment outcome versus patients who had a good treatment outcome at the indicated timepoints. Non-parametric Mann-Whitney U-test with Benjamini-Hochberg correction for multiple testing was applied to test for statistical differences between the groups.




Supplementary Figure S5. Scatter plots representing Pearson correlations between the longitudinal DEGs identified by dcRT-MLPA versus the same genes identified by RNA-Seq. Values are plotted as log2 FC (month six-diagnosis). Black line corresponds to line of best fit and shaded bands indicate confidence intervals.






Supplementary Figure S6. Scatter plot representing Pearson correlations between the longitudinal DEGs in TB patients who had a poor treatment outcome versus the longitudinal DEGs in TB patients who had a good treatment outcome. Values are plotted as log2 FC (month 6-diagnosis). Black line corresponds to line of best fit and shaded bands indicate confidence intervals. Red shaded areas indicate genes that were identified as DEGs only in patients who had a good treatment outcome and blue shaded areas indicate genes that were identified as DEGs only in patients who had a poor treatment outcome.




Supplementary Figure S7. Differential expression analysis of all TB patients from the South African and Indonesian cohorts categorized based on treatment outcome compared to their gene expression levels at diagnosis. (a) Volcano plots representing DEGs regulated during anti-TB treatment of TB patients from the South African cohort who had a good treatment outcome (left panel) or a poor treatment outcome (right panel). (b) Volcano plots representing DEGs regulated during anti-TB treatment obtrome (right panel). (b) Volcano plots representing DEGs regulated during anti-TB treatment of TB patients from the Indonesian cohort who had a good treatment outcome (left panel) or a poor treatment outcome (right panel). (a,b) The y-axis scales of the plots are harmonized per treatment outcome. -log10-transformed p-values are plotted against log2 FC. Genes with p <0.05 and log2 FC <-0.6 or >0.6 were labelled as DEGs.




**Supplementary Figure S8. Prediction of treatment outcome in RNA-Seq data from peripheral blood.** ROC curves showing the predictive power of (a) the gene signatures identified in the pooled cohort (South Africa and Indonesia) or (b) the Sweeney gene signature to classify TB patients at the indicated timepoints after initiation of anti-TB treatment into patients who had a good treatment outcome and patients who had a poor treatment outcome. Data were split into training and test sets (60/40). For each time point a gene signature was generated by RFE and a weighted model fitted using glmnet method. Weights of 1/frequency \* 0.5 were used. Abbreviations: AUC, area under the curve; CI, confidence interval.






Supplementary Figure S9. Identification of a delta (week two minus diagnosis) signature predicting the outcome of anti-TB treatment. ROC curve showing the predictive power of the gene signature identified in the balanced pooled cohort to classify TB patients into patients who had a good treatment outcome and patients who had a poor treatment outcome, using the RFE - RF model and LOOCV. The dataset was balanced by down-sampling to encompass the same number of individuals with poor and good treatment outcome. Abbreviations: AUC, area under the curve; CI, confidence interval.


medRxiv preprint doi: https://doi.org/10.1101/2022.02.08.22269796; this version posted February 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. a Venn diagram - within cohort perpetuits. Venn diagram - between cohorts to be the available under a CC-BY-ND 4.0 International license.



#### **C** Venn diagram - sampling methods at diagnosis



**Supplementary Figure S10. Venn diagrams showing the number of genes encompassing treatment outcome signatures as identified by RFE-RF models.** (a) Venn diagram displaying the number of unique and overlapping genes comparing diagnosis (blue), week two (orange) and month two (green) gene signatures obtained by random-downsampling. (b) Venn diagram displaying the number of unique and overlapping genes comparing the gene signatures in the current study (diagnosis, week two and month two; orange) obtained by random-downsampling with the gene signatures published by Sivakumaran et al. (blue). (c) Venn diagram displaying the number of unique and overlapping genes comparing the diagnosis gene signature obtained by random-downsampling (blue) with the diagnosis gene signature obtained by applying SMOTE sampling (orange) to balance the classes. Overlapping genes are annotated.



Supplementary Figure S11. Identification of a SMOTE diagnosis signature predicting the outcome of anti-TB treatment. ROC curves showing the predictive power of the gene signatures identified in the balanced pooled cohort (South Africa and Indonesia) and validated in the South African and Indonesian cohort or in an external Indian cohort. TB patients are classified into patients who had a good treatment outcome and patients who had a poor treatment outcome at diagnosis, using the RFE - RF model and LOOCV. The dataset was balanced by SMOTE to encompass the same number of individuals with poor and good treatment outcome. Abbreviations: AUC, area under the curve; CI, confidence interval.

# Supplementary Table S1. List of target genes for dcRT-MLPA.

Module	Gene
Immune cell subset markers - B cells	CD19
NK cells	NCAM1
T cell subset markers	CD3E
	CD4
	CD8A
	CCR7
	PTPRCv1
	PTPRCv2
	AIRE
	IL7R
Th1 associated / IFN signaling genes	CXCL10
Th1 associated genes	IFNG
	IL1B
	IL2
	IL15
	TBX21
	TNF
Th2 associated genes	GATA3
	IL4
	IL4δ2
	IL5
	IL6
	IL10
	IL13
Th9 associated genes	IL9
Th17 associated genes	IL17A
	RORC
	IL22RA1
Treg associated genes	CCL4
	CTLA4
	FOXP3
	IL2RA
	LAG3
	TGFB1
	TNFRSF18
Cytotoxicity markers	GNLY
	GZMA
	GZMB
Anontoois / Survival	PRF1
Apoptosis / Survival	CASP8 BCL2
	FASLG
	FASLG FLCN1
	TNFRSF1A
	TNFRSF1A TNFRSF1B
Mualaid associated games	CD14
Myeloid-associated genes	CD14 CD163
	CD163 CCL2
	CCL2 CCL3
I	CCLS

l	CCL5
	CCL22
	CXCL13
	IL12A
	IL12R IL12B
	IL23A
	FPR1
Chemokines	CCL11
chemokines	CCL13
	CCL19
	CXCL9
	CX3CL1
Pattern recognition receptors	CD209
	CLEC7A
	MRC1
	MRC1 MRC2
	NOD1
	NOD1 NOD2
	TLR1
	TLR1
	TLR2
	TLR4
	TLR5
	TLR6
	TLR7
	TLR8
	TLR9
	TLR10
Inflammasome components	NLRC4
r internet in the second se	NLRP1
	NLRP2
	NLRP3
	NLRP4
	NLRP6
	NLRP7
	NLRP10
	NLRP11
	NLRP12
	NLRP13
IFN signaling genes	CD274
	FCGR1A
	GBP1
	GBP2
	GBP5
	IFI6
	IFI16
	IFI35
•	

	IFI44
	IFI44L
	IFIH1
	IFIT2
	IFIT3
	IFIT5
	IFITM1/3
	INDO
	IRF7
	OAS1
	OAS2
	OAS3
	SOCS1
	STAT1
	STAT2
	TAP1
	TAP2
Inflammation	DSE
	MMP9
	SPP1
	TIMP2
	TNIP1
Cell growth / Proliferation	BMP6
	TGFBR2
	AREG
	EGF
	VEGF
Cell activation	HCK
	LYN
	SLAMF7
Small GTPases / (Rho) GTPase activating proteins	ASAP1
	RAB13
	RAB24
	RAB33A
	TAGAP
	TBC1D7
Anti-microbial activity	BPI
	LTF
E3 ubiquitin protein ligases	NEDD4L
Scavenger receptors	MARCO
G protein-coupled receptors	BLR1
Transcriptional regulators/activators	CAMTA1
	TWIST1
	ZNF331
	ZNF532
Intracellular transport	SEC14L1
·	KIF1B
Mitochondrial Stress / Proteasome	HPRT
Housekeeping	ABR
	B2M
	GAPDH
	GUSB
	0050

### Supplementary Table S7. Gene signatures for each timepoint - RNA-Seq

D	W. 1.0		
<u>Diagnosis</u>	Week 2	Month 2	<u>Month 6</u>
MADCAM1	FGFR3	CD79B	DNMT3B
MTFR2	ICAM3	PIK3CB	HAUS4
TM4SF1	SLC7A4	MEF2BNB-MEF2B	SLC22A18
CLCN1	PACSIN2	TCL1A	RTN4
WASF4P	HPN	TANGO6	CCRL2
ANKDD1B	ERGIC1	PTGES3	SERPINE2
HIST1H2BO	IL1R2	DOCK7	LYSMD2
TCTEX1D2	SSPN	ZNHIT6	WASH2P
RPSAP54	DOK4	KIF14	IL17RC
WASH4P	PRKCG	PARD6B	ARFIP1
AC026185.1	TCN1	E2F5	CCDC68
RPS2P44	GCM1	AK7	PPP1R14A
RP11-466P24.6	GAS2L3	MPZL2	RIMBP3
RP11-1105G2.4	SYT2	AKR1E2	Y_RNA
RP11-229P13.25	NR1I2	OXSR1	MIR140
MIR3136	TENM4	CNIH2	LEPROT
CTB-50L17.9	SLC45A3	ACBD7	RPL18P10
RP11-272L13.4	WNK2	TNF	AC099552.2
RP11-92K15.3	DPCD	PTGES3L	RP11-544A12.5
RP11-305L7.7			FLT1P1
KP11-303L/./	CXCL11	SPIB	
	B3GALNT1	USP32P1	RP11-295K2.3
	SLC22A1	IGHD	RP11-56M3.1
	HIST1H2AJ	GOLGA2P7	AC132186.1
	SNRNP35	AC096579.7	Clorf213
	CLCN1	RP11-458F8.1	UGDH-AS1
	CTD-3088G3.8	AC002543.2	RP11-175P13.3
	SULF2	IGKV1D-16	RP11-638I2.10
	CLEC4C	LINC00617	RP11-705O1.8
	RNU6-1079P	RP11-407G23.4	SENP3-EIF4A1
	AGAP7	RP11-588K22.2	RP11-401F2.3
	STARD7-AS1	RP11-325K4.2	RP11-1109F11.3
	YBX1P1	AL133153.1	U91328.22
	PRRT4	RP11-479F13.1	
	LINC01001		
	BCAS2P2		
	RP11-459O1.2		
	AL627309.1		
	IFNG-AS1		
	CTD-3051D23.4		
	RP4-647C14.3		
	CTD-2006K23.1		
	RP11-457M11.5		
	BX649553.4		
	CTB-39G8.3		
	MUC8		
	AC092299.8		
	110072277.0		

### Supplementary Table S8. Delta signature Good vs Poor obtained by pooling the study groups and the cohorts.

Gene	Module
GNLY	Cytotoxicity markers
MRC1	Pattern recognition receptors
GBP5	IFN signaling genes
NLRP1	Inflammasome components
FLCN1	Apoptosis - Survival
ZNF532	Transcriptional regulators - activators
IFIT2	IFN signaling genes

#### Delta (Week two - Diagnosis) Signature

Genes that appeared also in the diagnosis or week two gene signatures are shown in bold. Gene signatures were obtained by downsampling the majority class (Good treatment outcome).

## Supplementary Table S9. SMOTE signature Good vs Poor obtained by pooling the study groups and the cohorts.

#### **Diagnosis Signature**

Gene	Module
AREG	Cell growth - proliferation
BCL2	Apoptosis - Survival
CASP8	Apoptosis - Survival
CCL13	Chemokines
CD209	Pattern recognition receptors
CLEC7A	Pattern recognition receptors
CTLA4	Treg associated genes
CX3CL1	Chemokines
FCGR1A	IFN signaling genes
GBP1	IFN signaling genes
IL12B	Myeloid associated genes
LTF	Anti-microbial activity
NLRP3	Inflammasome components
STAT1	IFN signaling genes
TIMP2	Inflammation
TLR8	Pattern recognition receptors
TLR9	Pattern recognition receptors
TNFRSF1A	Apoptosis - Survival
ZNF331	Transcriptional regulators - activators

Gene signature obtained by applying SMOTE sampling technique. Genes that are also identified in the Diagnosis signature obtained by downsamling are shown in bold.